Medications remain the mainstay of epilepsy treatment, and to date there are no FDA-approved devices that provide an accurate means of detection for generalized tonic-clonic seizures (GTCS), or convulsions, during activities of daily living. Two new studies presented at the American Epilepsy Society’s 67th Annual Meeting in Washington D.C. provide data that warrants the development of non-invasive devices with the capability to signal the onset of an epileptic seizure and could be crucial to optimal patient dosing.
Hey, check out all the engineering jobs. Post your resume today!
